{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T06:09:58Z","timestamp":1792735798122,"version":"4.5.0"},"reference-count":46,"publisher":"MDPI AG","issue":"16","license":[{"start":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T00:00:00Z","timestamp":1755561600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostics"],"abstract":"<jats:p>Background: Anemia is a common comorbidity in heart failure (HF) and has been associated with adverse clinical consequences. This retrospective, descriptive cohort study examined phenotype-specific differences in anemia severity, clinical presentation, comorbid burden, and in-hospital management across HF subtypes classified by left ventricular ejection fraction (LVEF). Methods: We retrospectively analyzed 443 adult patients hospitalized with concurrent HF and anemia from January 2022 to December 2024. Patients were stratified by LVEF into HFrEF (&lt;40%), HFmrEF (40\u201349%), and HFpEF (\u226550%). All patients included met WHO criteria for anemia. Demographic, clinical, paraclinical, and therapeutic data were extracted, and descriptive statistical methods were used to evaluate intergroup differences. No formal time-to-event analyses (e.g., Kaplan\u2013Meier curves) were performed; instead, exploratory cumulative readmission analyses using fixed follow-up windows were conducted. In-hospital mortality was recorded and stratified by HF phenotype. Results: The cohort comprised 213 (48.0%) HFrEF, 118 (26.6%) HFmrEF, and 112 (25.3%) HFpEF patients. The distribution of anemia severity, management strategies, and comorbidity profiles varied significantly across phenotypes. Severe anemia predominated in the HFmrEF cohort (54.2%), whereas mild anemia was most common in HFpEF (52.1%) and HFrEF (52.1%). Mean hemoglobin concentrations were 8.39 \u00b1 1.79 g\/dL (HFmrEF), 9.07 \u00b1 2.47 g\/dL (HFpEF), and 8.62 \u00b1 1.94 g\/dL (HFrEF). Rates of atrial fibrillation (48.2% in HFpEF), hypertensive ECG changes (63.4% in HFpEF), and ischemic-lesion patterns (&gt;50% in HFrEF) differed by cohort. Echocardiographically, grade III mitral regurgitation and severe pulmonary hypertension each affected 25.4% of HFmrEF patients, whereas HFpEF patients most often exhibited grade II mitral regurgitation (42.9%) and moderate pulmonary hypertension (42.9%). HFrEF patients had severe pulmonary hypertension. Intravenous (IV) iron was the primary treatment modality, with highest utilization in HFmrEF. IV iron use ranged from 69.9% (HFrEF) to 84.8% (HFmrEF), with transfusion rates of 5.6% (HFrEF)\u201316.1% (HFpEF). Comorbid burdens differed by phenotype: HFrEF was associated with structural heart disease, HFmrEF with vascular and hepatic pathology, and HFpEF with metabolic and degenerative comorbidities. Discharge pharmacotherapy reflected phenotype-specific treatment patterns. Conclusions: This real-world descriptive analysis highlights substantial variation in anemia burden and management across the HF spectrum. While limited to descriptive findings, our analysis highlights the heterogeneity of anemia in HF and describes observed associations across phenotypes, without implying causality. These findings should be interpreted as hypothesis-generating. These findings are observational, exploratory, and cannot establish a causal relationship between intravenous iron use and survival.<\/jats:p>","DOI":"10.3390\/diagnostics15162079","type":"journal-article","created":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T10:59:01Z","timestamp":1755601141000},"page":"2079","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Anemia in Heart Failure: Diagnostic Insights and Management Patterns Across Ejection Fraction Phenotypes"],"prefix":"10.3390","volume":"15","author":[{"given":"Otilia","family":"\u021aica","sequence":"first","affiliation":[{"name":"Cardiology Clinic, Emergency County Clinical Hospital of Bihor, 410165 Oradea, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1405-6836","authenticated-orcid":false,"given":"Ovidiu","family":"\u021aica","sequence":"additional","affiliation":[{"name":"Department of Morphological Disciplines, Faculty of Medicine and Pharmacy, University of Oradea, 410073 Oradea, Romania"},{"name":"Pathology Department, Emergency County Clinical Hospital of Bihor, 410165 Oradea, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,8,19]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.15420\/cfr.2023.05","article-title":"Global Public Health Burden of Heart Failure: An Updated Review","volume":"9","author":"Shahim","year":"2023","journal-title":"Card. Fail. Rev."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1056\/NEJMoa0908355","article-title":"Ferric carboxymaltose in patients with heart failure and iron deficiency","volume":"361","author":"Anker","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"28","DOI":"10.15420\/cfr.2018:6:2","article-title":"Iron Therapy in Heart Failure: Ready for Primetime?","volume":"4","author":"Mordi","year":"2018","journal-title":"Card. Fail. Rev."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jchf.2018.07.015","article-title":"Iron Deficiency in Heart Failure: An Overview","volume":"7","author":"Ebner","year":"2019","journal-title":"JACC Heart Fail."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1093\/eurjhf\/hft083","article-title":"Iron deficiency is a key determinant of health-related quality of life in patients with chronic heart failure regardless of anaemia status","volume":"15","author":"Enjuanes","year":"2013","journal-title":"Eur. J. Heart Fail."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1056\/NEJMra041809","article-title":"Anemia of chronic disease","volume":"352","author":"Weiss","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1172\/JCI200420945","article-title":"IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin","volume":"113","author":"Nemeth","year":"2004","journal-title":"J. Clin. Investig."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jacc.2007.09.036","article-title":"Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: A randomized, controlled, observer-blinded trial","volume":"51","author":"Okonko","year":"2008","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ijcard.2015.11.178","article-title":"The impact of iron deficiency and anaemia on exercise capacity and outcomes in patients with chronic heart failure. Results from the Studies Investigating Co-morbidities Aggravating Heart Failure","volume":"205","author":"Ebner","year":"2016","journal-title":"Int. J. Cardiol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1093\/eurheartj\/ehu385","article-title":"Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency","volume":"36","author":"Ponikowski","year":"2015","journal-title":"Eur. Heart J."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1038\/s41591-025-03671-1","article-title":"Systematic review and meta-analysis of intravenous iron therapy for patients with heart failure and iron deficiency","volume":"31","author":"Anker","year":"2025","journal-title":"Nat. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1016\/S0140-6736(20)32339-4","article-title":"Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: A multicentre, double-blind, randomised, controlled trial","volume":"396","author":"Ponikowski","year":"2020","journal-title":"Lancet"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1016\/S0140-6736(22)02083-9","article-title":"Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): An investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial","volume":"400","author":"Kalra","year":"2022","journal-title":"Lancet"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1093\/eurheartj\/ehae086","article-title":"Intravenous iron for heart failure, iron deficiency definitions, and clinical response: The IRONMAN trial","volume":"45","author":"Cleland","year":"2024","journal-title":"Eur. Heart J."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1002\/ejhf.161","article-title":"Iron deficiency in a multi-ethnic Asian population with and without heart failure: Prevalence, clinical correlates, functional significance and prognosis","volume":"16","author":"Yeo","year":"2014","journal-title":"Eur. J. Heart Fail."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1002\/ejhf.3504","article-title":"Effect of correcting iron deficiency on the risk of serious infection in heart failure: Insights from the IRONMAN trial","volume":"27","author":"Foley","year":"2025","journal-title":"Eur. J. Heart Fail."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1136\/heartjnl-2022-322030","article-title":"Treating iron deficiency in patients with heart failure: What, why, when, how, where and who","volume":"110","author":"Graham","year":"2024","journal-title":"Heart"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1136\/heartjnl-2014-305669","article-title":"Iron deficiency: An emerging therapeutic target in heart failure","volume":"100","author":"Leclercq","year":"2014","journal-title":"Heart"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e011728","DOI":"10.1161\/CIRCHEARTFAILURE.124.011728","article-title":"Transferrin Saturation, Serum Iron, and Ferritin in Heart Failure: Prognostic Significance and Proteomic Associations","volume":"18","author":"Gan","year":"2025","journal-title":"Circ. Heart Fail."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1001\/jamacardio.2016.1161","article-title":"Prevalence and Outcomes of Anemia and Hematinic Deficiencies in Patients with Chronic Heart Failure","volume":"1","author":"Cleland","year":"2016","journal-title":"JAMA Cardiol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1053\/j.jvca.2020.07.016","article-title":"Heart Failure with Preserved Ejection Fraction: A Comprehensive Review and Update of Diagnosis, Pathophysiology, Treatment, and Perioperative Implications","volume":"35","author":"Pagel","year":"2021","journal-title":"J. Cardiothorac. Vasc. Anesth."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1016\/j.jacc.2006.08.034","article-title":"Etiology of anemia in patients with advanced heart failure","volume":"48","author":"Nanas","year":"2006","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/S0735-1097(96)00268-9","article-title":"Circulating levels of cytokines and their endogenous modulators in patients with mild to severe congestive heart failure due to coronary artery disease or hypertension","volume":"28","author":"Testa","year":"1996","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1080\/00015385.2017.1351239","article-title":"Impact of iron deficiency on exercise capacity and outcome in heart failure with reduced, mid-range and preserved ejection fraction","volume":"73","author":"Martens","year":"2018","journal-title":"Acta Cardiol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1002\/ehf2.12612","article-title":"The transition from hypertension to hypertensive heart disease and heart failure: The PREFERS Hypertension study","volume":"7","author":"Hellman","year":"2020","journal-title":"ESC Heart Fail."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e007840","DOI":"10.1161\/CIRCHEARTFAILURE.120.007840","article-title":"Right Heart Phenotype in Heart Failure with Preserved Ejection Fraction","volume":"14","author":"Guazzi","year":"2021","journal-title":"Circ. Heart Fail."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e32","DOI":"10.15420\/cfr.2022.03","article-title":"Breaking the Cycle of Heart Failure with Preserved Ejection Fraction and Atrial Fibrillation","volume":"8","author":"Khamboo","year":"2022","journal-title":"Card. Fail. Rev."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"\u021aica, O., \u021aica, O., Bunting, K.V., deBono, J., Gkoutos, G.V., Popescu, M.I., and Kotecha, D. (2022). Post-mortem examination of high mortality in patients with heart failure and atrial fibrillation. BMC Med., 20.","DOI":"10.1186\/s12916-022-02533-8"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.echo.2023.01.011","article-title":"Pulmonary Hypertension Phenotype can be Identified in Heart Failure with Reduced Ejection Fraction Using Echocardiographic Assessment of Pulmonary Artery Pressure with Supportive use of Pressure Reflection Variables","volume":"36","author":"Smith","year":"2023","journal-title":"J. Am. Soc. Echocardiogr."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Zhang, Y., Liu, B., Bunting, K.V., Brind, D., Thorley, A., Karwath, A., Lu, W., Zhou, D., Wang, X., and Mobley, A.R. (2024). Development of automated neural network prediction for echocardiographic left ventricular ejection fraction. Front. Med., 11.","DOI":"10.3389\/fmed.2024.1354070"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/ejhf.3024","article-title":"2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"26","author":"McDonagh","year":"2024","journal-title":"Eur. J. Heart Fail."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1001\/jama.2017.5427","article-title":"Effect of Oral Iron Repletion on Exercise Capacity in Patients with Heart Failure with Reduced Ejection Fraction and Iron Deficiency: The IRONOUT HF Randomized Clinical Trial","volume":"317","author":"Lewis","year":"2017","journal-title":"Jama"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1093\/eurheartj\/ehad344","article-title":"Sacubitril\/valsartan in heart failure with mildly reduced or preserved ejection fraction: A pre-specified participant-level pooled analysis of PARAGLIDE-HF and PARAGON-HF","volume":"44","author":"Vaduganathan","year":"2023","journal-title":"Eur. Heart J."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.ijcard.2014.03.169","article-title":"Iron deficiency and health-related quality of life in chronic heart failure: Results from a multicenter European study","volume":"174","author":"Enjuanes","year":"2014","journal-title":"Int. J. Cardiol."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"K\u00f6seo\u011flu, F.D., and \u00d6zlek, B. (2024). Anemia and Iron Deficiency Predict All-Cause Mortality in Patients with Heart Failure and Preserved Ejection Fraction: 6-Year Follow-Up Study. Diagnostics, 14.","DOI":"10.3390\/diagnostics14020209"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1159\/000531467","article-title":"Are the Four Pillars the Ideal Treatment for the Elderly?","volume":"148","author":"Teodorovich","year":"2023","journal-title":"Cardiology"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1002\/ejhf.580","article-title":"Efficacy of sacubitril\/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: The PARADIGM-HF trial","volume":"18","author":"Vardeny","year":"2016","journal-title":"Eur. J. Heart Fail."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/S0140-6736(21)01638-X","article-title":"Redefining \u03b2-blocker response in heart failure patients with sinus rhythm and atrial fibrillation: A machine learning cluster analysis","volume":"398","author":"Karwath","year":"2021","journal-title":"Lancet"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1002\/ejhf.3673","article-title":"Pathophysiology and clinical use of agents with vasodilator properties in acute heart failure. A scientific statement of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)","volume":"27","author":"Chioncel","year":"2025","journal-title":"Eur. J. Heart Fail."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"\u021aica, O., and \u021aica, O. (2025). Molecular Diagnostics in Heart Failure: From Biomarkers to Personalized Medicine. Diagnostics, 15.","DOI":"10.3390\/diagnostics15141807"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in Heart Failure with a Preserved Ejection Fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S0140-6736(22)01429-5","article-title":"SGLT-2 inhibitors in patients with heart failure: A comprehensive meta-analysis of five randomised controlled trials","volume":"400","author":"Vaduganathan","year":"2022","journal-title":"Lancet"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1159\/000533880","article-title":"Circulating Neuropeptide Y May Be a Biomarker for Diagnosing Atrial Fibrillation","volume":"148","author":"Jelavic","year":"2023","journal-title":"Cardiology"}],"container-title":["Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4418\/15\/16\/2079\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:30:42Z","timestamp":1760034642000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4418\/15\/16\/2079"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,19]]},"references-count":46,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["diagnostics15162079"],"URL":"https:\/\/doi.org\/10.3390\/diagnostics15162079","relation":{},"ISSN":["2075-4418"],"issn-type":[{"value":"2075-4418","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,19]]}}}